{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:54:03Z","timestamp":1790798043841,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Isoliquiritigenin (=\u20094,2\u2032,4\u2032-Trihydroxychalcone) (ILG) is a major constituent of the Glycyrrhizae Rhizoma that has significant neuroprotective functions. In the present study, we re-examined the potential of ILG to inhibit human monoamine oxidase (hMAO) in vitro and established its mechanism of inhibition through a kinetics study and molecular docking examination. ILG showed competitive inhibition of hMAO-A and mixed inhibition of hMAO-B with IC<jats:sub>50<\/jats:sub> values of 0.68 and 0.33\u00a0\u00b5M, respectively, which varied slightly from the reported IC<jats:sub>50<\/jats:sub> values. Since ILG has been reported to reduce dopaminergic neurodegeneration and psychostimulant-induced toxicity (both of which are related to dopamine and vasopressin receptors), we investigated the binding affinity and modulatory functions of ILG on dopamine and vasopressin receptors. ILG was explored as an antagonist of the D<jats:sub>1<\/jats:sub> receptor and an agonist of the D<jats:sub>3<\/jats:sub> and V<jats:sub>1A<\/jats:sub> receptors with good potency. An in silico docking investigation revealed that ILG can interact with active site residues at target receptors with low binding energies. These activities of ILG on hMAO and brain receptors suggest the potential role of the compound to ameliorate dopaminergic deficits, depression, anxiety, and associated symptoms in Parkinson\u2019s disease and other neuronal disorders.<\/jats:p>","DOI":"10.1038\/s41598-021-02843-6","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T11:02:38Z","timestamp":1638874958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Isoliquiritigenin, a potent human monoamine oxidase inhibitor, modulates dopamine D1, D3, and vasopressin V1A receptors"],"prefix":"10.1038","volume":"11","author":[{"given":"Ritu","family":"Prajapati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Hui","family":"Seong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ah","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9034-8868","authenticated-orcid":false,"given":"Jae Sue","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"2843_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI200317522","volume":"111","author":"S Przedborski","year":"2003","unstructured":"Przedborski, S., Vila, M. & Jackson-Lewis, V. Series introduction: Neurodegeneration: what is it and where are we?. J. Clin. Investig. 111, 3\u201310 (2003).","journal-title":"J. Clin. Investig."},{"key":"2843_CR2","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJM2003ra020003","volume":"348","author":"RL Nussbaum","year":"2003","unstructured":"Nussbaum, R. L. & Ellis, C. E. Alzheimer\u2019s disease and Parkinson\u2019s disease. N. Engl. J. Med. 348, 1356\u20131364 (2003).","journal-title":"N. Engl. J. Med."},{"key":"2843_CR3","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.drudis.2019.05.003","volume":"24","author":"SL Cheong","year":"2019","unstructured":"Cheong, S. L., Federico, S., Spalluto, G., Klotz, K.-N. & Pastorin, G. The current status of pharmacotherapy for the treatment of Parkinson\u2019s disease: Transition from single-target to multitarget therapy. Drug Discov. Today 24, 1769\u20131783 (2019).","journal-title":"Drug Discov. Today"},{"key":"2843_CR4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5742\/MEWFM.2020.93824","volume":"18","author":"A Abyad","year":"2020","unstructured":"Abyad, A. Parkinson's disease: An update on pathophysiology, epidemiology, diagnosis and management. Part 2: etiology and pathophysiology. Middle East J. Fam. Med. 18, 71\u201380 (2020).","journal-title":"Middle East J. Fam. Med."},{"key":"2843_CR5","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2174\/0929867311320130004","volume":"20","author":"M Lbolognesi","year":"2013","unstructured":"Lbolognesi, M. Polypharmacology in a single drug: Multitarget drugs. Curr. Med. Chem. 20, 1639\u20131645 (2013).","journal-title":"Curr. Med. Chem."},{"key":"2843_CR6","doi-asserted-by":"crossref","first-page":"8062","DOI":"10.1021\/acs.jafc.6b02954","volume":"64","author":"G Li","year":"2016","unstructured":"Li, G., Nikolic, D. & Van Breemen, R. B. Identification and chemical standardization of licorice raw materials and dietary supplements using UHPLC-MS\/MS. J. Agric. Food Chem. 64, 8062\u20138070 (2016).","journal-title":"J. Agric. Food Chem."},{"key":"2843_CR7","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3390\/molecules24091816","volume":"24","author":"YJ Han","year":"2019","unstructured":"Han, Y. J., Kang, B., Yang, E.-J., Choi, M.-K. & Song, I.-S. Simultaneous determination and pharmacokinetic characterization of glycyrrhizin, isoliquiritigenin, liquiritigenin, and liquiritin in rat plasma following oral administration of Glycyrrhizae radix extract. Molecules 24, 1816 (2019).","journal-title":"Molecules"},{"key":"2843_CR8","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/ptr.5348","volume":"29","author":"F Peng","year":"2015","unstructured":"Peng, F. et al. A review: The pharmacology of isoliquiritigenin. Phytother. Res. 29, 969\u2013977 (2015).","journal-title":"Phytother. Res."},{"key":"2843_CR9","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fnagi.2018.00348","volume":"10","author":"M Ramalingam","year":"2018","unstructured":"Ramalingam, M., Kim, H., Lee, Y. & Lee, Y.-I. Phytochemical and pharmacological role of liquiritigenin and isoliquiritigenin from radix Glycyrrhizae in human health and disease models. Front. Aging Neurosci. 10, 348 (2018).","journal-title":"Front. Aging Neurosci."},{"key":"2843_CR10","doi-asserted-by":"crossref","first-page":"153319","DOI":"10.1016\/j.phymed.2020.153319","volume":"78","author":"X Gu","year":"2020","unstructured":"Gu, X. et al. Isoliquiritigenin attenuates diabetic cardiomyopathy via inhibition of hyperglycemia-induced inflammatory response and oxidative stress. Phytomedicine 78, 153319 (2020).","journal-title":"Phytomedicine"},{"key":"2843_CR11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.freeradbiomed.2020.03.016","volume":"152","author":"D Shi","year":"2020","unstructured":"Shi, D. et al. The antioxidant activity and neuroprotective mechanism of isoliquiritigenin. Free Radic. Biol. Med. 152, 207\u2013215 (2020).","journal-title":"Free Radic. Biol. Med."},{"key":"2843_CR12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.intimp.2019.04.028","volume":"72","author":"X Zhu","year":"2019","unstructured":"Zhu, X. et al. Neuroprotective effects of isoliquiritigenin against cognitive impairment via suppression of synaptic dysfunction, neuronal injury, and neuroinflammation in rats with kainic acid-induced seizures. Int. Immunopharmacol. 72, 358\u2013366 (2019).","journal-title":"Int. Immunopharmacol."},{"key":"2843_CR13","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s10787-019-00592-7","volume":"27","author":"X Zhu","year":"2019","unstructured":"Zhu, X. et al. Neuroprotective and anti-inflammatory effects of isoliquiritigenin in kainic acid-induced epileptic rats via the TLR4\/MYD88 signaling pathway. Inflammopharmacology 27, 1143\u20131153 (2019).","journal-title":"Inflammopharmacology"},{"key":"2843_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12868-018-0483-3","volume":"20","author":"X Zhu","year":"2019","unstructured":"Zhu, X. et al. Isoliquiritigenin attenuates lipopolysaccharide-induced cognitive impairment through antioxidant and anti-inflammatory activity. BMC Neurosci. 20, 1\u201313 (2019).","journal-title":"BMC Neurosci."},{"key":"2843_CR15","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.2174\/138161210793176527","volume":"16","author":"M Naoi","year":"2010","unstructured":"Naoi, M. & Maruyama, W. Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr. Pharm. Des. 16, 2799\u20132817 (2010).","journal-title":"Curr. Pharm. Des."},{"key":"2843_CR16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","volume":"7","author":"MB Youdim","year":"2006","unstructured":"Youdim, M. B., Edmondson, D. & Tipton, K. F. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 7, 295\u2013309 (2006).","journal-title":"Nat. Rev. Neurosci."},{"key":"2843_CR17","doi-asserted-by":"publisher","first-page":"S287","DOI":"10.1038\/sj.bjp.0706464","volume":"147","author":"MB Youdim","year":"2006","unstructured":"Youdim, M. B. & Bakhle, Y. Monoamine oxidase: Isoforms and inhibitors in Parkinson\u2019s disease and depressive illness. Br. J. Pharmacol. 147, S287\u2013S296. https:\/\/doi.org\/10.1038\/sj.bjp.0706464 (2006).","journal-title":"Br. J. Pharmacol."},{"key":"2843_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1353-8020(99)00043-7","volume":"6","author":"P Foley","year":"2000","unstructured":"Foley, P., Gerlach, M., Youdim, M. B. & Riederer, P. MAO-B inhibitors: Multiple roles in the therapy of neurodegenerative disorders?. Parkinsonism Relat. Disord. 6, 25\u201347. https:\/\/doi.org\/10.1016\/s1353-8020(99)00043-7 (2000).","journal-title":"Parkinsonism Relat. Disord."},{"key":"2843_CR19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000116655","volume":"31","author":"A Mangoni","year":"1991","unstructured":"Mangoni, A. et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur. Neurol. 31, 100\u2013107 (1991).","journal-title":"Eur. Neurol."},{"key":"2843_CR20","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1248\/cpb.39.1238","volume":"39","author":"T Hatano","year":"1991","unstructured":"Hatano, T., Fukuda, T., Miyase, T., Noro, T. & Okuda, T. Phenolic constituents of licorice. III. Structures of glicoricone and licofuranone, and inhibitory effects of licorice constituents of monoamine oxidase. Chem. Pharm. Bull. 39, 1238\u20131243 (1991).","journal-title":"Chem. Pharm. Bull."},{"key":"2843_CR21","first-page":"949","volume":"21","author":"X Pan","year":"2000","unstructured":"Pan, X., Kong, L.-D., Zhang, Y., Cheng, C. & Tan, R.-X. In vitro inhibition of rat monoamine oxidase by liquiritigenin and isoliquiritigenin isolated from Sinofranchetia chinensis. Acta Pharmacol. Sin. 21, 949\u2013953 (2000).","journal-title":"Acta Pharmacol. Sin."},{"key":"2843_CR22","first-page":"4653","volume":"44","author":"Z Kong","year":"2019","unstructured":"Kong, Z., Sun, D.-M., Chen, A.-Q. & Hu, Y. Synthesis and monoamine oxidase B inhibitory activities of isoquiritigenin derivatives. Zhongguo Zhong Yao Za Zhi 44, 4653\u20134660 (2019).","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"2843_CR23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nsb732","volume":"9","author":"C Binda","year":"2002","unstructured":"Binda, C., Newton-Vinson, P., Hub\u00e1lek, F., Edmondson, D. E. & Mattevi, A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol. 9, 22\u201326 (2002).","journal-title":"Nat. Struct. Biol."},{"key":"2843_CR24","doi-asserted-by":"crossref","first-page":"12684","DOI":"10.1073\/pnas.0505975102","volume":"102","author":"L De Colibus","year":"2005","unstructured":"De Colibus, L. et al. Three-dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B. Proc. Natl. Acad. Sci. 102, 12684\u201312689 (2005).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"2843_CR25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2008.03.054","volume":"587","author":"EY Jang","year":"2008","unstructured":"Jang, E. Y. et al. Isoliquiritigenin suppresses cocaine-induced extracellular dopamine release in rat brain through GABAB receptor. Eur. J. Pharmacol. 587, 124\u2013128 (2008).","journal-title":"Eur. J. Pharmacol."},{"key":"2843_CR26","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s10571-011-9722-1","volume":"31","author":"Z Kawakami","year":"2011","unstructured":"Kawakami, Z., Ikarashi, Y. & Kase, Y. Isoliquiritigenin is a novel NMDA receptor antagonist in kampo medicine yokukansan. Cell. Mol. Neurobiol. 31, 1203\u20131212 (2011).","journal-title":"Cell. Mol. Neurobiol."},{"key":"2843_CR27","first-page":"e396","volume":"71","author":"J Kitanaka","year":"2011","unstructured":"Kitanaka, J. et al. Isoliquiritigenin suppresses methamphetamine-induced hyperlocomotion in mice. Neurosci. Res. 71, e396\u2013e397 (2011).","journal-title":"Neurosci. Res."},{"key":"2843_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-02087-x","volume":"8","author":"DO Sambo","year":"2017","unstructured":"Sambo, D. O. et al. The sigma-1 receptor modulates methamphetamine dysregulation of dopamine neurotransmission. Nat. Commun. 8, 1\u201318 (2017).","journal-title":"Nat. Commun."},{"key":"2843_CR29","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1007\/s11064-018-2528-5","volume":"43","author":"HN Mai","year":"2018","unstructured":"Mai, H. N. et al. Exposure to far infrared ray protects methamphetamine-induced behavioral sensitization in glutathione peroxidase-1 knockout mice via attenuating mitochondrial burdens and dopamine D1 receptor activation. Neurochem. Res. 43, 1118\u20131135 (2018).","journal-title":"Neurochem. Res."},{"key":"2843_CR30","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/joim.12049","volume":"273","author":"S Ares-Santos","year":"2013","unstructured":"Ares-Santos, S., Granado, N. & Moratalla, R. The role of dopamine receptors in the neurotoxicity of methamphetamine. J. Intern. Med. 273, 437\u2013453 (2013).","journal-title":"J. Intern. Med."},{"key":"2843_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2017.12.036","volume":"133","author":"NA Everett","year":"2018","unstructured":"Everett, N. A., McGregor, I. S., Baracz, S. J. & Cornish, J. L. The role of the vasopressin V1A receptor in oxytocin modulation of methamphetamine primed reinstatement. Neuropharmacology 133, 1\u201311 (2018).","journal-title":"Neuropharmacology"},{"key":"2843_CR32","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.3390\/ijms20123056","volume":"20","author":"P Maher","year":"2019","unstructured":"Maher, P. The potential of flavonoids for the treatment of neurodegenerative diseases. Int. J. Mol. Sci. 20, 3056 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"2843_CR33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.fitote.2017.11.009","volume":"124","author":"EI Mohamed","year":"2018","unstructured":"Mohamed, E. I. et al. Monoamine oxidases inhibitors from Colvillea racemosa: Isolation, biological evaluation, and computational study. Fitoterapia 124, 217\u2013223 (2018).","journal-title":"Fitoterapia"},{"key":"2843_CR34","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.3390\/molecules25173896","volume":"25","author":"GS Jeong","year":"2020","unstructured":"Jeong, G. S. et al. Inhibition of butyrylcholinesterase and human monoamine oxidase-B by the coumarin glycyrol and liquiritigenin isolated from Glycyrrhiza uralensis. Molecules 25, 3896 (2020).","journal-title":"Molecules"},{"key":"2843_CR35","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1021\/jm060441e","volume":"49","author":"L Novaroli","year":"2006","unstructured":"Novaroli, L. et al. Impact of species-dependent differences on screening, design, and development of MAO B inhibitors. J. Med. Chem. 49, 6264\u20136272 (2006).","journal-title":"J. Med. Chem."},{"key":"2843_CR36","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijbiomac.2019.06.167","volume":"137","author":"JM Oh","year":"2019","unstructured":"Oh, J. M. et al. Potent and selective inhibition of human monoamine oxidase-B by 4-dimethylaminochalcone and selected chalcone derivatives. Int. J. Biol. Macromol. 137, 426\u2013432 (2019).","journal-title":"Int. J. Biol. Macromol."},{"key":"2843_CR37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1254\/jphs.09153SC","volume":"111","author":"MJ Lee","year":"2009","unstructured":"Lee, M. J., Yang, C. H., Jeon, J.-P. & Hwang, M. Protective effects of isoliquiritigenin against methamphetamine-induced neurotoxicity in mice. J. Pharmacol. Sci. 111, 216\u2013220 (2009).","journal-title":"J. Pharmacol. Sci."},{"key":"2843_CR38","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1271\/bbb.110842","volume":"76","author":"CK Hwang","year":"2012","unstructured":"Hwang, C. K. & Chun, H. S. Isoliquiritigenin isolated from licorice Glycyrrhiza uralensis prevents 6-hydroxydopamine-induced apoptosis in dopaminergic neurons. Biosci. Biotechnol. Biochem. 76, 536\u2013543 (2012).","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"2843_CR39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.neuro.2018.07.011","volume":"68","author":"DG Lee","year":"2018","unstructured":"Lee, D. G., Min, J.-S., Lee, H.-S. & Lee, D.-S. Isoliquiritigenin attenuates glutamate-induced mitochondrial fission via calcineurin-mediated Drp1 dephosphorylation in HT22 hippocampal neuron cells. Neurotoxicology 68, 133\u2013141 (2018).","journal-title":"Neurotoxicology"},{"key":"2843_CR40","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9692321","volume":"2020","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Isoliquiritigenin attenuates anxiety-like behavior and locomotor sensitization in rats after repeated exposure to nicotine. Evid. Based Complementary Altern. Med. 2020, 9692321. https:\/\/doi.org\/10.1155\/2020\/9692321(2020).","journal-title":"Evid. Based Complementary Altern. Med."},{"key":"2843_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41422-021-00482-0","volume":"31","author":"Y Zhuang","year":"2021","unstructured":"Zhuang, Y. et al. Mechanism of dopamine binding and allosteric modulation of the human D1 dopamine receptor. Cell Res. 31, 1\u20134 (2021).","journal-title":"Cell Res."},{"key":"2843_CR42","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1126\/science.1197410","volume":"330","author":"EY Chien","year":"2010","unstructured":"Chien, E. Y. et al. Structure of the human dopamine D3 receptor in complex with a D2\/D3 selective antagonist. Science 330, 1091\u20131095 (2010).","journal-title":"Science"},{"key":"2843_CR43","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1046\/j.1432-1033.2000.01472.x","volume":"267","author":"N Cotte","year":"2000","unstructured":"Cotte, N. et al. Conserved aromatic residues in the transmembrane region VI of the V1A vasopressin receptor differentiate agonist vs. antagonist ligand binding. Eur. J. Biochem. 267, 4253\u20134263 (2000).","journal-title":"Eur. J. Biochem."},{"key":"2843_CR44","first-page":"2463","volume":"49","author":"MJ \u015alusarz","year":"2006","unstructured":"\u015alusarz, M. J., Sikorska, E., \u015alusarz, R. & Ciarkowski, J. Molecular docking-based study of vasopressin analogues modified at positions 2 and 3 with N-methylphenylalanine: Influence on receptor-bound conformations and interactions with vasopressin and oxytocin receptors. J. Neural Transm. 49, 2463\u20132469 (2006).","journal-title":"J. Neural Transm."},{"key":"2843_CR45","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/403039","volume":"2011","author":"S Hisahara","year":"2011","unstructured":"Hisahara, S. & Shimohama, S. Dopamine receptors and Parkinson's disease. Int. J. Med. Chem. 2011, 403039. https:\/\/doi.org\/10.1155\/2011\/403039 (2011).","journal-title":"Int. J. Med. Chem."},{"key":"2843_CR46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40262-016-0449-5","volume":"56","author":"T M\u00fcller","year":"2017","unstructured":"M\u00fcller, T. & Foley, P. Clinical pharmacokinetics and pharmacodynamics of safinamide. Clin. Pharmacokinet. 56, 251\u2013261 (2017).","journal-title":"Clin. Pharmacokinet."},{"key":"2843_CR47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/13543776.2018.1427735","volume":"28","author":"S Carradori","year":"2018","unstructured":"Carradori, S., Secci, D. & Petzer, J. P. MAO inhibitors and their wider applications: A patent review. Expert Opin. Ther. Pat. 28, 211\u2013226 (2018).","journal-title":"Expert Opin. Ther. Pat."},{"key":"2843_CR48","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S1353-8020(09)70836-3","volume":"15","author":"F Stocchi","year":"2009","unstructured":"Stocchi, F. Dopamine receptor agonists in the treatment of advanced Parkinson\u2019s disease. Parkinsonism Relat. Disord. 15, S54\u2013S57 (2009).","journal-title":"Parkinsonism Relat. Disord."},{"key":"2843_CR49","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jns.2006.05.024","volume":"248","author":"MR Lemke","year":"2006","unstructured":"Lemke, M. R., Brecht, H. M., Koester, J. & Reichmann, H. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson\u2019s disease. J. Neurol. Sci. 248, 266\u2013270 (2006).","journal-title":"J. Neurol. Sci."},{"key":"2843_CR50","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00210-019-01694-3","volume":"393","author":"SM Gu","year":"2020","unstructured":"Gu, S. M., Cha, H. J., Seo, S. W., Hong, J. T. & Yun, J. Dopamine D1 receptor antagonist reduces stimulant-induced conditioned place preferences and dopamine receptor supersensitivity. Naunyn Schmiedebergs Arch. Pharmacol. 393, 131\u2013138 (2020).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"2843_CR51","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2174\/187152710793361496","volume":"9","author":"J Lud Cadet","year":"2010","unstructured":"Lud Cadet, J., Jayanthi, S., T McCoy, M., Beauvais, G. & Sheng Cai, N. Dopamine D1 receptors, regulation of gene expression in the brain, and neurodegeneration. CNS Neurol. Disord. Drug Targets 9, 526\u2013538 (2010).","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"2843_CR52","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1523\/JNEUROSCI.0852-07.2007","volume":"27","author":"E Santini","year":"2007","unstructured":"Santini, E. et al. Critical involvement of cAMP\/DARPP-32 and extracellular signal-regulated protein kinase signaling in l-DOPA-induced dyskinesia. J. Neurosci. 27, 6995\u20137005 (2007).","journal-title":"J. Neurosci."},{"key":"2843_CR53","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.nbd.2011.11.005","volume":"45","author":"S Ares-Santos","year":"2012","unstructured":"Ares-Santos, S. et al. Dopamine D1 receptor deletion strongly reduces neurotoxic effects of methamphetamine. Neurobiol. Dis. 45, 810\u2013820 (2012).","journal-title":"Neurobiol. Dis."},{"key":"2843_CR54","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1523\/JNEUROSCI.0837-06.2006","volume":"26","author":"JM Van Kampen","year":"2006","unstructured":"Van Kampen, J. M. & Eckman, C. B. Dopamine D3 receptor agonist delivery to a model of Parkinson\u2019s disease restores the nigrostriatal pathway and improves locomotor behavior. J. Neurosci. 26, 7272\u20137280 (2006).","journal-title":"J. Neurosci."},{"key":"2843_CR55","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.neulet.2018.08.011","volume":"684","author":"W Wang","year":"2018","unstructured":"Wang, W., Liu, L., Chen, C., Jiang, P. & Zhang, T. Protective effects of dopamine D2\/D3 receptor agonist piribedil on learning and memory of rats exposed to global cerebral ischemia\u2013reperfusion. Neurosci. Lett. 684, 181\u2013186 (2018).","journal-title":"Neurosci. Lett."},{"key":"2843_CR56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bbr.2006.12.009","volume":"178","author":"N Egashira","year":"2007","unstructured":"Egashira, N. et al. Impaired social interaction and reduced anxiety-related behavior in vasopressin V1A receptor knockout mice. Behav. Brain Res. 178, 123\u2013127 (2007).","journal-title":"Behav. Brain Res."},{"key":"2843_CR57","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.npp.1300360","volume":"29","author":"IF Bielsky","year":"2004","unstructured":"Bielsky, I. F., Hu, S.-B., Szegda, K. L., Westphal, H. & Young, L. J. Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology 29, 483\u2013493 (2004).","journal-title":"Neuropsychopharmacology"},{"key":"2843_CR58","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1254\/jphs.FP0071498","volume":"106","author":"CK Lee","year":"2008","unstructured":"Lee, C. K. et al. Isoliquiritigenin inhibits tumor growth and protects the kidney and liver against chemotherapy-induced toxicity in a mouse xenograft model of colon carcinoma. J. Pharmacol. Sci. 106, 444\u2013451 (2008).","journal-title":"J. Pharmacol. Sci."},{"key":"2843_CR59","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jep.2014.12.043","volume":"162","author":"H Gong","year":"2015","unstructured":"Gong, H. et al. A protective mechanism of licorice (Glycyrrhiza uralensis): Isoliquiritigenin stimulates detoxification system via Nrf2 activation. J. Ethnopharmacol. 162, 134\u2013139 (2015).","journal-title":"J. Ethnopharmacol."},{"key":"2843_CR60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1208\/s12248-013-9544-9","volume":"16","author":"X Qiao","year":"2014","unstructured":"Qiao, X. et al. Identification of key licorice constituents which interact with cytochrome P450: Evaluation by LC\/MS\/MS cocktail assay and metabolic profiling. AAPS J. 16, 101\u2013113 (2014).","journal-title":"AAPS J."},{"key":"2843_CR61","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.reprotox.2016.10.004","volume":"66","author":"S Mahalingam","year":"2016","unstructured":"Mahalingam, S., Gao, L., Eisner, J., Helferich, W. & Flaws, J. A. Effects of isoliquiritigenin on ovarian antral follicle growth and steroidogenesis. Reprod. Toxicol. 66, 107\u2013114 (2016).","journal-title":"Reprod. Toxicol."},{"key":"2843_CR62","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1021\/acsfoodscitech.0c00152","volume":"1","author":"R Prajapati","year":"2021","unstructured":"Prajapati, R., Park, S. E., Park, H. J., Jung, H. A. & Choi, J. S. Identification of a potent and selective human monoamine oxidase-A inhibitor, glycitein, an isoflavone isolated from Pueraria lobata flowers. ACS Food Sci. Technol. 1, 538\u2013550 (2021).","journal-title":"ACS Food Sci. Technol."},{"key":"2843_CR63","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/md19060326","volume":"19","author":"P Paudel","year":"2021","unstructured":"Paudel, P. et al. In vitro and in silico characterization of G-protein coupled receptor (GPCR) targets of phlorofucofuroeckol-A and dieckol. Mar. Drugs 19, 326 (2021).","journal-title":"Mar. Drugs"},{"key":"2843_CR64","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1021\/ci300413h","volume":"53","author":"M Ko\u0142aczkowski","year":"2013","unstructured":"Ko\u0142aczkowski, M., Bucki, A., Feder, M. & Paw\u0142owski, M. Ligand-optimized homology models of D1 and D2 dopamine receptors: Application for virtual screening. J. Chem. Inf. Model. 53, 638\u2013648 (2013).","journal-title":"J. Chem. Inf. Model."},{"key":"2843_CR65","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/1471-2105-10-421","volume":"10","author":"C Camacho","year":"2009","unstructured":"Camacho, C. et al. BLAST+: Architecture and applications. BMC Bioinform. 10, 421 (2009).","journal-title":"BMC Bioinform."},{"key":"2843_CR66","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nmeth.1818","volume":"9","author":"M Remmert","year":"2012","unstructured":"Remmert, M., Biegert, A., Hauser, A. & S\u00f6ding, J. HHblits: Lightning-fast iterative protein sequence searching by HMM-HMM alignment. Nat. Methods 9, 173\u2013175 (2012).","journal-title":"Nat. Methods"},{"key":"2843_CR67","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1002\/elps.200900140","volume":"30","author":"N Guex","year":"2009","unstructured":"Guex, N., Peitsch, M. C. & Schwede, T. Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: A historical perspective. Electrophoresis 30, S162\u2013S173 (2009).","journal-title":"Electrophoresis"},{"key":"2843_CR68","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.bpj.2011.10.024","volume":"101","author":"D Xu","year":"2011","unstructured":"Xu, D. & Zhang, Y. Improving the physical realism and structural accuracy of protein models by a two-step atomic-level energy minimization. Biophys. J. 101, 2525\u20132534 (2011).","journal-title":"Biophys. J."},{"key":"2843_CR69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6","volume":"9","author":"DS Goodsell","year":"1996","unstructured":"Goodsell, D. S., Morris, G. M. & Olson, A. J. Automated docking of flexible ligands: Applications of AutoDock. J. Mol. Recognit. 9, 1\u20135 (1996).","journal-title":"J. Mol. Recognit."},{"key":"2843_CR70","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","volume":"58","author":"DE Pires","year":"2015","unstructured":"Pires, D. E., Blundell, T. L. & Ascher, D. B. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J. Med. Chem. 58, 4066\u20134072 (2015).","journal-title":"J. Med. Chem."},{"key":"2843_CR71","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 42717 (2017).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02843-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02843-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02843-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T18:00:57Z","timestamp":1670090457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02843-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2843"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-02843-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,7]]},"assertion":[{"value":"12 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23528"}}